Page 65 - Read Online
P. 65

Farkas et al. J Cancer Metastasis Treat 2022;8:37  https://dx.doi.org/10.20517/2394-4722.2022.89  Page 11 of 13

               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2022.


               REFERENCES
               1.       Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med 2017;5:236.  DOI  PubMed  PMC
               2.       Mott FE. Mesothelioma: a review. Ochsner J 2012;12:70.  PubMed  PMC
               3.       Henley SJ, Larson TC, Wu M, et al. Mesothelioma incidence in 50 states and the district of Columbia, United States, 2003-2008. Int J
                   Occup Environ Health 2013;19:1-10.  DOI  PubMed  PMC
               4.       Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005.
                   Cancer Causes Control 2009;20:935-44.  DOI  PubMed
               5.       Beasley MB, Galateau-Salle F, Dacic S. Pleural mesothelioma classification update. Virchows Arch 2021;478:59-72.  DOI  PubMed
               6.       Gelvez-Zapata SM, Gaffney D, Scarci M, Coonar AS. What is the survival after surgery for localized malignant pleural mesothelioma?
                   Interact Cardiovasc Thorac Surg 2013;16:533-7.  DOI  PubMed  PMC
               7.       Marchevsky AM, Khoor A, Walts AE, et al. Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of
                   serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Mod Pathol 2020;33:281-96.  DOI
                   PubMed
               8.       Editorial Board WC of T. Thoracic tumours: WHO classification of tumours, 5th ed. World Health Organization: Geneva, Switzerland,
                   2021.
               9.       Travis WD, Brambilla E, Burke A, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart, 5th
                   ed. International Agency for Research on Cancer: Lyon, France, 2015.
               10.      Nicholson AG, Sauter JL, Nowak AK, et al. EURACAN/IASLC proposals for updating the histologic classification of pleural
                   mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol 2020;15:29-49.  DOI  PubMed
               11.      Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the
                   consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 2018;142:89-108.  DOI  PubMed
               12.      Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO classification of tumors of the pleura: advances since the 2015
                   classification. J Thorac Oncol 2022;17:608-22.  DOI  PubMed
               13.      Rosen LE, Karrison T, Ananthanarayanan V, et al. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural
                   mesothelioma: a multi-institutional study. Mod Pathol 2018;31:598-606.  DOI  PubMed
               14.      Kadota K, Suzuki K, Colovos C, et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural
                   mesothelioma. Mod Pathol 2012;25:260-71.  DOI  PubMed  PMC
               15.      Pelosi G, Papotti M, Righi L, et al. Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal. J Thorac
                   Oncol 2018;13:1750-61.  DOI  PubMed
               16.      Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol
                   2010;23:470-9.  DOI  PubMed
               17.      Mansfield AS, Symanowski JT, Peikert T. Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in
                   clinical trials. Lung Cancer 2014;86:133-6.  DOI  PubMed  PMC
               18.      Galateau Salle F, Le Stang N, Tirode F, et al. Comprehensive molecular and pathologic evaluation of transitional mesothelioma
                   assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH reference
                   center. J Thorac Oncol 2020;15:1037-53.  DOI  PubMed  PMC
               19.      Galateau Salle F, Le Stang N, Nicholson AG, et al. New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-
                   institutional  evaluation  by  the  international  mesothelioma  panel  from  the  MESOPATH  reference  center.  J  Thorac  Oncol
                   2018;13:1189-203.  DOI  PubMed  PMC
               20.      Schulte JJ, Chapel DB, Attanoos R, et al. Comparison of nuclear grade, necrosis, and histologic subtype between biopsy and resection
                   in pleural malignant mesothelioma: an international multi-institutional analysis. Am J Clin Pathol 2021;156:989-99.  DOI  PubMed
               21.      Chirieac LR, Hung YP, Foo WC, et al. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant
                   pleural mesothelioma. Cancer 2019;125:4164-71.  DOI  PubMed  PMC
               22.      Vigneswaran WT, Kircheva DY, Ananthanarayanan V, et al. Amount of epithelioid differentiation is a predictor of survival in
                   malignant pleural mesothelioma. Ann Thorac Surg 2017;103:962-6.  DOI  PubMed
               23.      Zhang YZ, Brambilla C, Molyneaux PL, et al. Presence of pleomorphic features but not growth patterns improves prognostic
                   stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade. Histopathology 2020;77:423-36.  DOI
               24.      Zhang YZ, Brambilla C, Molyneaux PL, et al. Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in
   60   61   62   63   64   65   66   67   68   69   70